Circulating N-terminal pro-atrial natriuretic peptide is an independent predictor of left ventricular hypertrophy in the general population. The Tromso Study

European Heart Journal

Volumn 20, Issue 10, 1999, Pages 755-763

  Schirmer, H ^a   Omland, T ^b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Echocardiography; Heart failure; Hypertrophy; Natriuretic peptides; Population

Indexed keywords

ATRIAL NATRIURETIC FACTOR;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; GENDER; HEART EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; VALVULAR HEART DISEASE;

EID: 0033135229     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1998.1396     Document Type: Article

References (41)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the framingham heart study. N Engl J Med 1990; 322: 1561-6.
2. Messerli FH, Schmieder R. Left ventricular hypertrophy. A cardiovascular risk factor in essential hypertension. Drugs 1986; 31 (Suppl 4): 192-201 .
3. Verdecchia P, Schillaci G, Borgioni C et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97: 48-54.
4. MacMahon SW, Wilcken DE, Macdonald GJ. The effect of weight reduction on left ventricular mass. A randomized controlled trial in young, overweight hypertensive patients. N Engl J Med 1986; 314: 334-9.
5. Kokkinos PF, Narayan P, Colleran JA et al. Effects of regular exercise on blood pressure and left ventricular hypertrophy in african-american men with severe hypertension. N Engl J Med 1995; 333: 1462-7.
6. Liebson PR, Grandits GA, Dianzumba S et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995; 91: 698-706.
7. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: Comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation 1997; 95: 2007-14.
8. Crow RS, Prineas RJ, Rautaharju P, Hannan P, Liebson PR. Relation between electrocardiography and echocardiography for left ventricular mass in mild systemic hypertension (results from treatment of mild hypertension study). Am J Cardiol 1995; 75: 1233-8.
9. Christensen G, Leistad E. Atrial systolic pressure, as well as stretch, is a principal stimulus for release of ANF. Am J Physiol 1997; 272: H820-6.
10. Lee RT, Pfeffer JM, Pfeffer MA, Seidman CE. Atrial natriuretic factor gene expression in ventricles of rats with spontaneous biventricular hypertrophy. J Clin Invest 1988; 81: 431-4.
11. Benedict CR, Johnstone DE, Weiner DH et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: A report from the registry of studies of left ventricular dysfunction. SOLVD Investigators. J Am Coll Cardiol 1994; 23: 1410-20.
12. Lerman A, Gibbons RJ, Rodeheffer RJ et al. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet 1993; 341: 1105-9.
13. Richards AM, Crozier IG, Yandle TG, Espiner EA, Ikram H, Nicholls MG. Brain natriuretic factor: Regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J 1993; 69: 414-17.
14. Davidson NC, Naas AA, Hanson JK, Kennedy NS, Coutie WJ, Struthers AD. Comparison of atrial natriuretic peptide B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol 1996; 77: 828-31.
15. Omland T, Aakvaag A, Vik-Mo H. Plasma cardiac natriuretic peptide determination as a screening test for detection of patients with mild left ventricular impairment. Heart 1996; 76: 232-7.
16. Yamamoto K, Burnett Jr JC, Jougasaki M et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28: 988-94.
17. Sundsfjord JA, Thibault G, Larochelle P, Cantin M. Identification and plasma concentrations of the N-terminal fragment of proatrial natriuretic factor in man. J Clin Endocrinol Metab 1988; 66: 605-10.
18. Bjartveit K, Foss OP, Gjervig T, Lund-Larsen PG. The cardiovascular disease study. Acta Med Scand 1979; 1-70.
19. Thelle DS, Førde OH, Try K, Lehmann EH. The Tromsø heart study. Methods and main results of the cross-sectional study. Acta Med Scand 1976; 200: 107-18.
20. Bønaa KH, Thelle DS. Association between blood pressure and serum lipids in a population. The Tromsø Study. Circulation 1991; 83: 1305-14.
21. Bønaa KH, Arnesen E. Association between heart rate and atherogenic blood lipid fractions in a population. The Tromsø Study. Circulation 1992; 86: 394-405.
22. O'Rourke RA, Hanrath P, Henry WN et al. Report of the joint international society and federation of cardiology/world health organization task force on recommendations for standardization of measurements from M-mode echocardiograms. Circulation 1984; 69: 854A-7A.
23. Devereux RB, Alonso DR, Lutas EM et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 1986; 57: 450-8.
24. de Simone G, Verdecchia P, Schillaci G, Devereux RB. Clinical impact of various geometric models for calculation of echocardiographic left ventricular mass. J Hypertens 1998; 16: 1207-14.
25. Levy D, Savage DD, Garrison RJ, Anderson KM, Kannel WB, Castelli WP. Echocardiographic criteria for left ventricular hypertrophy: The framingham heart study. Am J Cardiol 1987; 59: 956-60.
26. Schirmer H, Lunde P, Rasmussen K. Prevalence of left ventricular hypertrophy in a general population; The Tromsø study. Eur Heart J 1999; 20: 429-380.
27. Hall C, Aaberge L, Stokke O. In vitro stability of N-terminal proatrial natriuretic factor in unfrozen samples: An important prerequisite for its use as a biochemical parameter of atrial pressure in clinical routine (letter). Circulation 1995; 91: 911.
28. SAS Institute Inc. SAS/STAT User's Guide. Version 6, Fourth Ed., Cary, NC, USA: SAS Institute Inc., 1990.
29. Schoonjans F. MedCalc Computer Program for Statistics in Medicine. Mariakerke, Belgium, MedCalc Software, 1993: 82.
30. Kohno M, Horio T, Yokokawa K et al. Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy: Changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor. Am J Med 1995; 98: 257-65.
31. Haug C, Metzele A, Kochs M, Hombach V, Grunert A. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end-diastolic pressure. Clin Cardiol 1993; 16: 553-7.
32. Yoshimura M, Yasue H, Okumura K et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993; 87: 464-9.
33. Nakamura M, Kawata Y, Yoshida H et al. Relationship between plasma atrial and brain natriuretic peptide concentration and hemodynamic parameters during percutaneous transvenous mitral valvulotomy in patients with mitral stenosis. Am Heart J 1992; 124: 1283-8.
34. Bonarjee VV, Omland T, Nilsen DW, Caidahl K, Sundsfjord JA, Dickstein K. Plasma proatrial natriuretic factor (1-98) concentration after myocardial infarction: Relation to indices of cardiac and renal function. Br Heart J 1995; 73: 511-16.
35. McDonagh TA, Robb SD, Morton JJ et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9-13.
36. Gottlieb SS, Kukin ML, Ahern D, Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure [published erratum appears in J Am Coll Cardiol 1989 Sep;14:812]. J Am Coll Cardiol 1989; 13: 1534-9.
37. Hall C, Rouleau JL, Moye L et al. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation 1994; 89: 1934-42.
38. Omland T, Aakvaag A, Bonarjee VS et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal pro-atrial natriuretic peptide. Circulation 1996; 93: 1963-9.
39. Wallén T, Landahl S, Hedner T, Hall C, Saito Y, Nakao K. Atrial natriuretic peptides predict mortality in the elderly. J Intern Med 1997; 241: 269-75.
40. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55: 613-18.
41. Woythaler JN, Singer SL, Kwan OL et al. Accuracy of echocardiography versus electrocardiography in detecting left ventricular hypertrophy: Comparison with post mortem mass measurements. J Am Coll Cardiol 1983; 2: 305-11.